FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)		1										1
1. Name and Address of Reporting Person* FROM STEPHEN				2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director _X_ Officer (give title below) Other (specify below) President and CEO					
(Last) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLY OAKS ROAD, SUITE 108				3. Date of Earliest Transaction (Month/Day/Year) 11/02/2020						Pr	esident and	JEO		
(Street) WALTHAM, MA 02452				4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City) (State) (Zip)			Table I - Non-Derivative Securities Acqu					ired, Disposed of, or Beneficially Owned						
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	f Code (Instr. 8)		(A) or	4. Securities Acquired (A) or Disposed of (D (Instr. 3, 4 and 5)				ollowing	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership
					Code	· V	Amoui	(A) or (D)	Price	(msu. 3 a	nu +)		\ /	(Instr. 4)
Common	Stock		11/02/2020		F(1)		623	D	\$ 3.51	78,581			D	
Reminder:	Report on a s	separate line fo		Derivative Securit	ies Acqu	Person the	sons wi tained i form di Disposed	ho respo in this fo splays a of, or Ber	rm are curre neficial	e not requ ntly valid	OMB con	formation spond unle trol numbe	ss	1474 (9-02)
1 Title of	l ₂	3. Transaction		e.g., puts, calls, wa	arrants, o	-				itle and	8. Price of	9. Number	of 10.	11 Notes
Security	2. Conversion or Exercise Price of Derivative Security	Date	Year) Execution Da	te, if Transaction Number Code of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		and (Mo	and Expiration Date (Month/Day/Year)		Am Und Sec			Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owners Form of Derivat Security Direct (or Indir	Beneficial Ownersh (Instr. 4)
				Code V	(A) (E		e ercisable	Expiratio Date	n Title	Amount or e Number of Shares				

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
FROM STEPHEN C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLY OAKS ROAD, SUITE 108 WALTHAM, MA 02452	X		President and CEO				

Signatures

/s/ Sarah Romano, Attorney-in-Fact*	11/03/2020		
**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale of shares to cover taxes due on restricted stock that vested on 11/01/2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.